对青皮肤衍生的循环作为选择性母质酶抑制剂的结构见解
Agata Gitlin-Domagalska1, Malihe Hassanzadeh2, Aleksandra Helbik-Maciejewska1
1Department of Molecular Biochemistry, University of Gdańsk, 80-309, Gdańsk, Poland.
European journal of medicinal chemistry
|November 7, 2025
概括
研究人员使用来自HV-BBI的循环酸开发出强效和选择性的母酶抑制剂. 化合物6显示纳米分子效能和高选择性,为与母质酶相关的疾病提供了有前途的治疗策略.
科学领域:
- 生物化学 生物化学
- 蛋白酶抑制剂开发开发 蛋白酶抑制剂开发
- 药用化学 医学化学
背景情况:
- 孕酶是一种II型跨膜血清蛋白酶,对上皮质完整性和癌症进展至关重要.
- 由于与其他蛋白酶 (如TMPRSS6.6) 的结构相似性,开发选择性母质酶抑制剂具有挑战性.
研究的目的:
- 调查HV-BBI衍生的循环对母质酶抑制活性和选择性的研究.
- 确定负责强烈和选择性母质酶抑制的关键结构特征.
主要方法:
- 来自HV-BBI的循环的合成和选.
- 结构-活性关系研究,包括氨酸扫描和C端修饰.
- 分子动力学模拟以阐明结合相互作用.
- 在体外细胞测试以评估活性和细胞毒性.
主要成果:
- 化合物6,13个残留周期性,证明了纳米分子效能和对母质酶的1000倍选择性超过TMPRSS6.
- 胺的C末端对功效至关重要;用碳氧酸盐替代显著降低了活性.
- 鉴定出Lys5,Ser6,Ile7和Arg10的残留物对母质酶结合至关重要.
- 化合物6显示细胞活性没有细胞毒性.
结论:
- 从HV-BBI衍生的循环代表了开发高度选择性的母酶抑制剂的有希望的支架.
- 这项研究的结构性见解可以指导未来的母质酶向治疗的合理设计.
- 化合物6是进一步临床前开发的有价值的化合物.
相关概念视频
Feedback Inhibition
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Sharpless Epoxidation
The conversion of allylic alcohols into epoxides using the chiral catalyst was discovered by K. Barry Sharpless and is known as Sharpless epoxidation. The use of a chiral catalyst enables the formation of one enantiomer of the product in excess. This chiral catalyst is mainly a chiral complex of titanium tetraisopropoxide and tartrate ester (specific stereoisomer). The stereoisomer used in the chiral catalyst dictates the formation of the enantiomer of the product. In other words, the use of...
Radical Chain-Growth Polymerization: Overview
Chain-growth or addition polymerization is successive addition reactions of monomers with a polymer chain. In radical chain-growth polymerization, the reaction proceeds via a free-radical intermediate. The free radical is formed from radical initiators, which spontaneously generate free radicals by homolytic fission. Organic peroxides (such as dibenzoyl peroxide, as shown in Figure 1) or azo compounds are popular radical initiators. A low concentration ratio of radical initiator to monomer is...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...


